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Epidemiological data from the last years show an increasing trend of incidence and mortality of cholangiocarcinoma (CC)
worldwide. Many pathophysiologic aspects of this neoplasia are still unknown and need to be fully discovered. However, several
progresses were recently made in order to establish the molecular mechanisms involved in the transformation and growth of
malignant cholangiocytes. The principal concept that at least seems to be established is that cholangiocarcinogenesis is a multistep
cellular process evolving from a normal condition of the epithelial biliary cells through a chronic inﬂammation status ending
with malignant transformation. The bad prognosis related to CC justiﬁes why a better identiﬁcation of the molecular mechanisms
involved in the growth and progression of this cancer is required for the development of eﬀective preventive measures and valid
treatment regimens. This Paper describes the scientiﬁc progresses made in the last years in deﬁning the molecular pathways
implicated in the generation of this devastating disease.
1.Introduction
Cholangiocarcinoma is originated by a malignant trans-
formation of cholangiocytes, the epithelial cells lining the
biliary ducts [1]. Since biliary cancers may arise from every
portion of the biliary tree, they are anatomically classiﬁed
as intrahepatic or extrahepatic [1]. Epidemiological data
show that intrahepatic cholangiocarcinoma is increasing in
incidence, prevalence, and mortality worldwide [2, 3]. In
particular, in the past three decades, a progressive increase
of mortality for intrahepatic CC has been reported, while
mortality for extrahepatic CC is stable or slightly decreasing
[3].
The poor prognosis of this cancer is also explained
from the fact that no useful tools for early diagnosis
for this neoplasia are still available. Because of, the lack
of speciﬁc symptoms coupled with high invasiveness and
frequent involvement of critical anatomical organs [1, 4],
the patient typically presents with an unresectable disease at
the diagnostic approach. This aspect justiﬁes why a surgical
curative treatment is often impossible. Besides surgery,
the other types of treatments for CC are chemotherapy
and radiotherapy [1]. However, CC cells do not respond
or weakly respond to these approaches, which thus have
often a palliative role. Recent therapeutic options include
brachytherapy and photodynamic therapy (PDT), with
promising results [1, 4].
CC develops from the accumulation of genetic and
epigenetic alterations in regulatory genes in cholangiocytes
thatleadtotheactivationofoncogenesandthedysregulation
of tumor suppressor genes (TSGs) [5–8]. The principal
characteristics of malignant cholangiocytes can be summa-
rized in (i) uncontrolled growth, (ii) high capacity of tissue
invasiveness, and (iii) capacity to metastasize [5, 8]. In this
paper, we have described in detail the principal molecular
mechanisms involved in every passage of the multistep
process of cholangiocarcinogenesis.
2.MolecularMechanismsof
Cholangiocarcinogenesis
The molecular mechanisms involved in the development of
CC are incompletely deﬁned in detail, although in the last
years, several studies have contributed to codify them, at
least in part [5]. With the term “cholangiocarcinogenesis”
are named all the complex mechanisms that lead to the2 International Journal of Hepatology
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Figure 1: Proposed mechanisms leading to transformation of
normal biliary cells into malignant cholangiocytes. Cholangiocar-
cinoma cells express altered molecular mechanisms, which enhance
cell proliferation, decrease apoptosis, and increase the capacity of
tissue invasion, stromal proliferation, and angiogenesis.
malignant transformation of cholangiocytes. These mech-
anisms can be simply described as a multistep process
(Figure 1).CCusuallydevelopsinanenvironmentofchronic
inﬂammation of bile ducts with consequent cholangiocyte
damage associated with the obstruction of bile ﬂow [1, 5].
This tumor, especially when originating in the perihilar bile
ducts, can develop in normal liver [5, 9].
Primary sclerosing cholangitis (PSC) is the most rec-
ognized risk factor for CC development [9]. Other risk
factors for this cancer are speciﬁc parasites of endemic
regions of Asia such as Opisthorchis viverrini, Clonorchis
sinensis,a n dSchistosoma Japonica and bacteria such as
Salmonella typhi [9, 10]. Hepatolithiasis, Caroli’s disease,
congenital choledochal cysts, bilioenteric surgical drainage
and anomalous pancreaticobiliary junction, age greater than
65 years, bile duct adenoma, papillomatosis, liver cirrhosis,
smoking, diabetes mellitus, thorotrast, dioxin and vinyl
chloride intoxication, and HIV and HCV infections [9,
10] are also risk conditions for CC. However, the role of
most of these conditions as predisposing factors for biliary
cancer is still debated. Independently from the presence of
one of the mentioned factors, the malignant transforma-
tion of cholangiocyte arises in a background of chronic
inﬂammation. The high amount of cytokines and factors
secreted during chronic inﬂammatory processes triggers
and maintains the process of cholangiocarcinogenesis [5, 8]
(Figure 1). Molecules participating in chronic inﬂammation
promote neoplastic process by damaging protooncogenes,
DNA mismatch repair genes/proteins, and tumor suppressor
genes involved in cell growth, apoptosis, invasiveness, and
neoangiogenesis. The ﬁnal result is the uncontrolled cell
proliferation and invasion (Figure 1).
Such as in many other cancer types, K-ras, p53, p14ARF,
p16INK4a, and β-catenin genes can be mutated during the
development of CC [6].
Two other genes recently described as implicated in the
development of CC are NKG2D and AID. The natural killer
group 2, member D cell receptor, also known as NKG2D, is
expressed by NK cells and T-lymphocytes and plays a critical
role in tumor surveillance by cell-mediated cytotoxicity [11].
Melum et al. recently showed that two single nucleotide
polymorphisms (SNPs) of the NKG2D gene were associated
with an increased risk of CC in PSC-aﬀected patients [12].
Contrarily, homozygous condition for the no-risk alleles is
related with a low risk of CCs [12].
Activation-induced cytidine deaminase (AID) is a mem-
ber of the DNA/RNA-editing enzyme family. Recently, it was
shown that AID production was signiﬁcantly increased in
human biopsies of PSC and CC-aﬀected patients compared
with normal liver parenchyma [13]. Aberrant expression of
AID in biliary cells resulted in the generation of somatic
mutations in tumor-related genes such as p53, c-myc and the
promoterregionoftheINK4A/p16 sequences[13].Theaber-
rant expression of AID gene induced by proinﬂammatory
cytokinesstrengthensthelinkbetweenchronicinﬂammation
of the biliary tract and CC development [13].
3.MolecularPathwaysImplicatedin
Cholangiocarcinogenesis
3.1. IL-6. IL-6 has an important role in the pathogenesis and
growth of CC [14]. The mitogenic eﬀect of IL-6 is suggested
from the fact that the concentration of this molecule is
increased during chronic inﬂammation of the biliary tract,
a condition predisposing CC development [15]. IL-6 acts
by both an autocrine and a paracrine manner stimulat-
ing several intracellular pathways involved in survival and
growth of malignant cholangiocytes [16]. Among them,
p44/p42 and p38 MAPKs have been largely studied [17].
Tadlok et al. showed that activation of p38 MAPK by IL-
6 decreases expression of p21(WAF1/CIP1), a cell cycle
controller protein, and mediates growth independent of
anchorage signals, whereas activation of p44/p42 MAPK
mediates an anchorage signal-dependent growth pathway
[17]. IL-6 also inﬂuences the apoptotic process of malignant
cholangiocytes. Several studies showed that IL-6 upregulates
myeloid cell leukemia-1 or Mcl-1, a potent key antiapoptotic
Bcl-2 family member protein. It has been recently shown
that this eﬀect of IL-6 is mediated by increased activation
of STAT-3 (that is constitutively activated in malignant
cholangiocytes), which regulates Mcl-1 transcription thusInternational Journal of Hepatology 3
increasing resistance to apoptosis [18]. In addition, Mcl-
1 increases cancer cell resistance to tumor-necrosis-factor-
related apoptosis-inducing ligand (TRAIL) [19] and, there-
fore, this molecule appears to have a fundamental role in CC
development [20]. Conversely, inhibition of IL-6-induced
iperexpression of Mcl-1 restores sensitivity to TRAIL [21].
3.2. JAK/STAT. The Janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathway is one of
the key signaling mechanisms in CC cells, mediating their
resistance to apoptosis [20] .I nar e c e n ts t u d y ,B l e c h a c ze t
al. showed that the multikinase inhibitor sorafenib may also
block JAK/STAT signaling with consequent inhibition of
CC growth [22]. The authors demonstrated that sorafenib
induces STAT3 dephosphorylation by stimulating phos-
phataseSHP2activity,sensitizesCCcellstoTRAIL-mediated
apoptosis, and is therapeutic in a syngeneic rat, orthotopic
CC model that mimics human disease [22].
3.3. TGFβ. TGFβ is a cytokine implicated in several cell
f u n c t i o n ss u c ha sg r o w t h ,d i ﬀerentiation, migration, apop-
tosis, adhesion, survival, and immunity. Several cell types
of the liver secrete this cytokine [21]. Cholangiocytes, for
example, express TGFβ in course of cholestasis but not
in normal conditions [23]. It has been shown that TGFβ
inhibitsproliferationofhumanCCcellsthroughmodulation
of the p21 cyclin dependent kinase inhibitor [24]. However,
the mutations of TGFβ receptor and the alterations of
intracellular signaling mediators (e.g., Smad4) together with
the intracellular overexpression of cyclin D1 [25, 26]i nC C
cells induce a resistance to the inhibitory eﬀect of TGFβ cells
[27]. In addition, the lack of TGFβ signaling also stimulates
the deposition of ﬁbrotic tissue, abundantly expressed by
biliary malignancies [27].
3.4. Smad4. DCP4/Smad4 is a tumor suppressor gene and
also a downstream of TGFβ signaling [28]. Recently, it has
been shown that Smad4 interacts with PTEN, another tumor
suppressorgene,inordertoregulatecellularcycleandescape
the process of cholangiocarcinogenesis [29]. To strength this
data, the blockage of these tumor suppressor genes favors the
development of CC [29, 30]. It was also demonstrated that
pTNMstageofintrahepaticCCappearstobecorrelatedwith
the degree of Smad4 loss [30].
3.5. ErbB-2. The protooncogene-encoded receptor tyrosine
kinase ErbB-2 is overexpressed in malignant cholangiocytes
and plays an important role in the development and
progression of biliary malignancies [31–33]. ErbB-2 acts in
two diﬀerent manners: ﬁrst of all stimulates the proliferation
of CC cells, then ErbB-2 stimulates the production of COX-
2, which interacts with a subunit of the IL-6 receptor
forming a complex [34]. This eﬀect suggests a close link
between IL-6 and ErbB-2 signaling [1, 34]. The mitogenic
eﬀect of ErbB-2 is also suggested from the fact that when
normal cholangiocytes are transfected with the neu (the rat
homologue of ErbB-2) oncogene, they undergo a malignant
transformation that resembles the molecular aspects of
human CC [35].
3.6. COX-2. The enzyme cyclooxygenase (COX) is respon-
sible of the generation of prostaglandins, expressed in the
courseoftheprocessofinﬂammation.COXexistsintwospe-
ciﬁc isoforms: COX-1, normally expressed in many cell types
and regulating the homeostatic functions of prostaglandins,
and COX-2, the inducible isoform, which can be stimulated
by a variety of molecules, such as cytokines and lipopolysac-
charides [36]. The expression of COX-2 is major during
inﬂammation, condition predisposing the development of
CC [36]. Moreover, in rat CC cells, overexpression of COX-
2s t i m u l a t e sc e l lg r o w t h[ 37] while antisense depletion of
COX-2inhibitscellproliferation[37].Recentstudiesshowed
that COX-2 is activated in human CC cells in vitro [38]b y
oxysterols, derivatives from cholesterol, which are present in
bile of patients in course of cholestasis and inﬂammatory
processes of the biliary tract [39]. The mitogenic eﬀect
of COX-2 towards CC cells justiﬁes why the inhibition
of COX-2-mediated pathway could represent a strategy to
prevent CC development and growth. At this regard, recent
data demonstrated that selective COX-2 inhibitors (e.g.,
celecoxib) reduce proliferation of CC cells by stimulating
apoptosis [31, 37, 40, 41]. These studies also showed that
the inhibitory eﬀect towards CC cell growth by celecoxib
was accompanied by an inhibition of PDK1 and PTEN,
with a consequent reduction of Akt phosphorylation [42].
Moreover, celecoxib inhibits CC cells proliferation through
activation of cyclin-dependent kinase inhibitors p21waf1/cip1
and p27kip1, with consequent cell cycle arrest at G1/S phase
[43]. Sirica et al. recently demonstrated a link between the
increase of COX-2 expression and CC development since the
amount of this cytokine is high in cholangiocytes obtained
from livers aﬀected by PSC [31] ,aw e l lk n o w nr i s kf a c t o r
for CC [9]. These promising in vitro data, however, do not
correspond to a good outcome in clinical practice since
not all COX-2 inhibitors were shown to have a beneﬁt in
reducingCCcellgrowth[37]andalsobecausetheuseofhigh
doses of COX-2 inhibitors could cause serious side eﬀects
[37].
3.7. NO. Inducible nitric oxide (NO) synthase (iNOS)
is an enzyme highly expressed during inﬂammatory and
malignant processes of the biliary tract [44]. The activation
of iNOS in course of inﬂammation determines an increase
of intracellular NO, which triggers the process of cholan-
giocarcinogenesis by diﬀerent ways: (1) inhibits DNA repair
system thus allowing an accumulation of DNA damage and
mutations [8, 45]; (2) stimulates COX-2 expression [44].
The carcinogenic eﬀect of NO is at least in part due to
Notch-1 signaling [46] .T h er o l ep l a y e db yN Oa n dN o t c h -
1 in the development of biliary malignancies, as well as
pancreatic cancer, is suggested by the evidence that Notch-
1 is hyperexpressed both in cholangiocytes of PSC-aﬀects
patients and in CC cells where it colocalizes with iNOS
[46]. A recent study by Ishimura et al. showed that iNOS is
able to stimulate COX-2 expression through NO generation.4 International Journal of Hepatology
In particular, iNOS enhances COX-2 expression through
activation of p38 MAPK and JNK1/2 [44]. The link between
these two proteins explains their important role in the
development and growth of CC [44].
3.8. Apoptosis. The process of apoptosis is fundamental to
maintain the homeostasis of the biliary epithelium because
it permits to remove the cells deeply damaged and with no
reversible genomic mutations [47, 48]. After this premise,
it is clear that a defect of apoptotic process favorites the
survival of mutated cholangiocytes, which could go through
a series of other mutations ending with the malignant
transformation of the cell [47, 48].
Bcl-2 is a superfamily of antiapoptotic proteins. Bcl-2,
which represents the prototype of this family [49] and is
expressed in CC cells in a high amount. In these malignant
cells,which possess a higher apoptotic thresholdwith respect
to normal cholangiocytes [49], Bcl-2 exerts its antiapoptotic
activity by reducing caspase 3 activation by preventing
cytochrome-c release from the mitochondria [49].
Several other factors are implicated in the dysregulation
of cholangiocyte apoptosis [8]. Among them, NO inhibits
apoptosis of biliary epithelial cells. At this regard, the
transfection of CC cells with nitric-oxide-synthase- (NOS-)
cDNA induces a resistance to etoposide-induced apoptosis,
an event that happens by caspase 9 nitrosylation [50].
Furthermore, Notch-1 and COX-2 reduce TRAIL-
mediated apoptosis [21] and high levels of COX-2 inhibit
Fas-inducedapoptosisinCCcells[21].Tostrengthenedthese
data, a recent study demonstrated that celecoxib, a selective
COX-2 inhibitor, induces cell death by apoptosis by the
inhibition of the PI3-kinase signaling [37, 41].
The cytokine tumor-necrosis-factor-related apoptosis-
inducing ligand (TRAIL) selectively stimulates apoptosis
onlyinmalignantcellswithouthavinganytoxicityinnormal
tissues [51, 52]. CC cells resist TRAIL-induced apoptosis
because they express high levels of myeloid cell leukemia
protein-1(Mcl-1)[19].Thus,whenspeciﬁcsmall-interfering
mRNA or stable transfection with Mcl-1 small hairpin RNA
block Mcl-1 expression, CC cells become sensitive to TRAIL-
induced apoptosis [19, 53]. The expression of Mcl-1 is
also stimulated by bile acids, abundant in the course of
cholestasis. Among them, deoxycholic acid, for example,
increases Mcl-1 expression by blocking protein degradation
through activation of an EGFR/Raf-1 pathway [54]. Indeed,
Raf-1 inhibitors block the increase of Mcl-1, rendering the
cells much more sensitive to Fas-induced apoptosis [55]. All
these data suggest that TRAIL could be a target for novel
drugs for the management of biliary tumors [56].
3.9. VEGF. Biliary tumors proliferate surrounded by a rich
vascular network, which provides an adequate support of
oxygenandmetabolitestomalignantcholangiocytesinorder
to enhance tumor development and growth [1, 57]. The pro-
liferation of blood vessels is favored by high levels of vascular
endothelial growth factor (VEGF) [57, 58]. This protein is
stimulated by TGF-β and β-catenin [59] and is expressed
by the surrounding mesenchymal cells and, even if in a
lesserextent,bythemalignantcellsthemselves.Thisevidence
suggests the existence of an autocrine/paracrine mechanism
for the VEGF production by malignant cholangiocytes [60].
3.10. Estrogens. It is well known the mitogenic eﬀect of
estrogens for CC cells. At this regard, 17-β estradiol stim-
ulates human CC cells growth [61] while tamoxifen, an
estrogen antagonist, decreases the proliferation of these cells
in vitro and in vivo [61] by stimulating apoptosis through
the Fas/APO-1 (CD95) signaling pathway via a calmodulin-
dependent mechanism [62]. Alvaro et al. demonstrated that
human intrahepatic CC cells express receptors for both
estrogens and insulin-like growth factor 1 (IGF-1), which
cooperate in the modulation of enhancing cell growth
and reducing apoptosis [63]. Furthermore, HuH-28 human
intrahepatic CC cell line expresses VEGF-A, VEGF-C, and
related receptors, which are enhanced by stimulation with
estrogens [64], and the stimulatory eﬀect of 17beta-estradiol
is blocked by estrogen receptor or insulin-like growth factor-
1 receptor antagonists [64]. These data demonstrate that
estrogens stimulate the proliferation of human CC by
inducing the expression and secretion of vascularendothelial
growth factor [64]. The result of these studies could be
applied tothemanagementofbiliary malignancies inclinical
practice. In fact, measuring IGF-1 levels in bile could
help distinguish extrahepatic CC from pancreatic cancer
or benign biliary stenosis and blocking estrogen, IGF-1,
and VEGF receptors could be crucial to arrest CC cell
proliferation [65].
3.11. Neuropeptides and Hormones. In the last years, many
studies described as a multitude of hormones and neu-
ropeptides are able to interact and regulate CC cells growth
and invasion. Among them, gastrin, endothelin, serotonin,
secretin,histamine,theα-2-adrenoreceptorUK14,304,NPY,
GABA, leptin, and opioid receptor modulators regulate the
proliferation and apoptosis of CC cells [66–75]. All these
novel data could contribute to clarify the complex mecha-
nisms governing the process of cholangiocarcinogenesis.
4. Conclusion
The increasing worldwide incidence of CC together with the
lack of its eﬀective therapeutic tools explains the growing
general interest for the study of this cancer type. The bad
prognosis of people aﬀected by CC is given by the fact
that this cancer is often diagnosed when already at an
advanced stage. Unfortunately, at this point, only palliative
approaches are possible. With these premises, in the recent
years, many researchers have focused their studies on the
investigation of the molecular mechanisms involved in the
development andgrowthofCC.Severalworksdemonstrated
that the conditions of cholestasis and chronic inﬂammation
induce a local release of a network of mitogenic factors
that induce genomic damages thus triggering the malignant
transformation of cholangiocytes. The complete codiﬁcation
of molecular pathways involved in the pathogenesis of CC isInternational Journal of Hepatology 5
mandatory to discover novel tools for an early diagnosis and
an eﬃcacious speciﬁc therapy.
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